«New method to
generate human antibodies.»
Not exact matches
In the current study, Vanderbilt researchers led by graduate student Andrew Flyak, the paper's first author, used a high - efficiency method they developed to quickly isolate and
generate large quantities of monoclonal
human antibodies from the blood of survivors of a 2007 outbreak in Uganda who were infected by the Bundibugyo ebolavirus.
The new technology was tested in mice for the ability to
generate antibodies in their blood stream that would target
human PSMA as well as target PSMA - positive tumors.
«We need more research to investigate the levels of
antibodies generated when
humans get infected, and how they work in women during pregnancy.
Professor Hayday added: «This is very significant because
antibodies make up one of the largest sectors of the pharmaceutical market, and one of the great quests in the pharmaceutical industry is to be able to routinely
generate antibodies against
human proteins implicated in diseases.
Humans have evolved
antibodies against it when we eat meat or are exposed to alpha - Gal -
generating microbes in our environment.
New data published in Immunity further illuminate how some
human beings
generate powerful, HIV - blocking
antibodies.
Fascinated by the efficient way the
human immune system
generates a rapid response to create a near - infinite variety of
antibodies, researchers have «hijacked» that machinery and used it to evolve a...
Antibodies generated in
humans to DENV are of particular clinical relevance, because they have the potential during a subsequent infection to protect from or increase the risk of developing DHF.
By Day 42, immunized animals
generated plasma Abeta
antibodies that labeled Abeta plaques in
human, AD transgenic mouse and vervet brains; bound Abeta1 - 7; and recognized monomeric and oligomeric Abeta but not full - length amyloid precursor protein nor its C - terminal fragments.
A trpE / apoA - IV fusion protein was
generated to produce a goat
antibody to
human apoA - IV.
WRAIR and collaborators will share data related to assays designed to measure
antibody responses following vaccination with ZPIV, biologic samples
generated during the performance of animal studies, and biologic samples
generated during the performance of early
human trials assessing the safety and immunogenicity of ZPIV.
The
antibodies listed above in the immunocytochemistry section were also used on eye sections together with a cocktail of
antibodies generated against
human - specific markers (HSM) to identify
human cells (the Oka blood group antigen, mouse TRA -1-85, 1 ∶ 10 (a kind gift from Peter Andrews, University of Sheffield, Sheffield, UK) together with mouse
human nuclear antigen, 1 ∶ 1000, Millipore).
So to
generate autoimmunity against Neu5gc incorporated in
human cells, B cells must first be triggered to form high - affinity anti-Neu5gc
antibodies by meeting bacterial pathogens who have incorporated Neu5gc into their cell walls.